Upregulated expression of heparanase in the vitreous of patients with proliferative diabetic retinopathy originates from activated endothelial cells and leukocytes

Purpose To determine and interrelate the levels of heparanase, syndecan‐1 and vascular endothelial growth factor (VEGF) in proliferative diabetic retinopathy (PDR), and to study the production of heparanase by human retinal microvascular endothelial cells (HRMEC) and its effect on HRMEC barrier func...

Full description

Saved in:
Bibliographic Details
Published in:Acta ophthalmologica (Oxford, England) England), 2016-10, Vol.94 (S256), p.n/a
Main Authors: Abu El Asrar, A., Nawaz, M.I., Mohammad, G., Van den Eynde, K., Siddiquei, M.M., Mousa, A., de Hertogh, G., Geboes, K., Opdenakker, G.
Format: Article
Language:English
Subjects:
Assaying
CD45 antigen
Chloride resistance
Cobalt
Cobalt chloride
Diabetes
Diabetes mellitus
Diabetic retinopathy
Electrical resistance
Endothelial cells
Enzyme-linked immunosorbent assay
Glucose
Immunohistochemistry
Interleukin 1
Leukocytes
Membranes
Microvasculature
Ophthalmology
Retina
Retinopathy
Syndecan
Tumor necrosis factor-α
Vascular endothelial growth factor
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To determine and interrelate the levels of heparanase, syndecan‐1 and vascular endothelial growth factor (VEGF) in proliferative diabetic retinopathy (PDR), and to study the production of heparanase by human retinal microvascular endothelial cells (HRMEC) and its effect on HRMEC barrier function. Methods Vitreous samples from 33 PDR and 27 nondiabetic patients, epiretinal membranes from 16 patients with PDR and HRMEC were studied by enzyme‐linked immunosorbent assay, immunohistochemistry, and Western blot analysis. The effect of heparanase on HRMEC barrier function was evaluated by transendothelial electrical resistance. Results We showed a significant increase in the expression of heparanase, syndecan‐1 and VEGF in vitreous samples from PDR patients compared to nondiabetic controls. (p 
ISSN:1755-375X
1755-3768
DOI:10.1111/j.1755-3768.2016.0442